Open AccessCytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients
Author(s) -
Abdulkareem Albekairy,
Abdulmalik Alkatheri,
Shiro Fujita,
Alan W. Hemming,
Richard J. Howard,
Alan Reed,
Janet L. Karlix
Publication year - 2013
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.108484
Subject(s) - tacrolimus , cyp3a4 , cyp3a5 , medicine , pharmacokinetics , liver transplantation , gastroenterology , pharmacology , genotype , dosing , single nucleotide polymorphism , pharmacogenetics , pharmacogenomics , trough level , transplantation , cytochrome p450 , biology , metabolism , gene , biochemistry
Tacrolimus is a macrolide immunosuppressant used for prevention of allograft rejection in organ transplantation and metabolized in the liver and intestine by cytochrome P450 3A4 (CYP3A4) enzyme. A single nucleotide polymorphism (SNP) in the CYP3A4 promoter region has been identified. It has been shown that the presence of CYP3A4FNx011B allele (variant GG) is associated with a reduced catalytic activity of CYP3A4 in vivo. The aim of this study was to determine the role of CYP3A4FNx011B on tacrolimus dosing and clinical outcome in liver transplant recipients.